E28362
Based on 1 Customer Validation
E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 94.51%
- CAS No.: 930017-01-9
- Formule: C16H19N3O3
- Masse moléculaire:301.34
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
E28362 (5-20 μM; 18 h) significantly decreases PCSK9 secretion from HepG2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2
-
Concentration:5, 10, 20 μM
-
Incubation Time:18 h
-
Result:Reduced PCSK9 secretion to ~70 pg/mL at 5 μM, ~80 pg/mL at 10 μM, and ~75 pg/mL at 20 μM, compared to the 0 μM control (~100 pg/mL).
E28362 (administered via oral gavage daily at 20-60 mg/kg/day for 12 consecutive weeks) reduces plasma VLDL-C and LDL-C levels, increases hepatic LDLR protein levels, and significantly decreases atherosclerotic lesion burden in ApoE-/- mice fed a Western diet[2].
E28362 (60 mg/kg/day; oral gavage; daily administration; 12 weeks) reduces plasma TC, TG and LDL-C levels, downregulates plasma and hepatic PCSK9 levels, upregulates hepatic LDLR levels, and significantly decreases atherosclerotic lesion burden in human PCSK9D374Y-overexpressing mice fed a Western-style diet[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male golden hamsters (7 weeks old; high-fat diet-induced hyperlipidemia model)[2]
-
Dosage:6.7 mg/kg/day; 20 mg/kg/day; 60 mg/kg/day
-
Administration:i.g.; daily; 4 weeks
-
Result:Reduced plasma total cholesterol (TC) by 21.50%, triglyceride (TG) by 53.51%, and low-density lipoprotein-cholesterol (LDL-C) by 16.97% at 6.7 mg/kg/day.
Reduced plasma TC by 23.22%, TG by 52.59%, and LDL-C by 43.64% at 20 mg/kg/day.
Reduced plasma TC by 28.97%, TG by 47.10%, and LDL-C by 23.05%, and significantly reduced plasma PCSK9 levels at 60 mg/kg/day.
Significantly reduced liver TC content at all three doses; significantly reduced liver TG content at 20 mg/kg/day.
Reduced hepatic steatosis, ballooning, and lipid droplet accumulation at all doses; significantly reduced plasma alanine aminotransferase (ALT) levels at 60 mg/kg/day.
Significantly increased hepatic LDLR protein levels relative to control at all three doses.
-
Animal Model:Male C57BL/6J mice (6 weeks old; human PCSK9 D374Y overexpression-induced atherosclerosis model)[2]
-
Dosage:60 mg/kg/day
-
Administration:i.g.; daily; 12 weeks
-
Result:Significantly reduced plasma TC, TG, and LDL-C levels relative to control.
Confirmed reduced cholesterol levels in VLDL and LDL particle fractions via FPLC analysis.
Significantly reduced en face aortic plaque area and aortic root lesion area relative to control.
Significantly decreased hepatic PCSK9 protein levels and increased hepatic LDLR protein levels relative to control.
Significantly reduced plasma PCSK9 levels.
Chemical Information
-
CAS No. 930017-01-9
-
Appearance Solid
-
Masse moléculaire 301.34
-
Formule C16H19N3O3
-
Color White to off-white
-
SMILES
O=C1NC(CN(CC(O)C)C2=O)=C2C(C3=CC=C(C)C=C3)N1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yue J, et al. Chemotherapy-Induced Bone Marrow Suppression: A Bibliometrics Analysis. J Multidiscip Healthc. 2025;18:1895-1911. Published 2025 Apr 7. [Content Brief]
[2]. Wang WZ, et al. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis. Acta Pharmacol Sin. 2024;45(10):2119-2133. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
E28362 Related Classifications
HY-162562 Related Classifications
Powered by Bioz